A Phase 4 interventional study of standard dose indomethacin and low dose indomethacin in Post-ERCP Pancreatitis, sponsored by Changhai Hospital. Recruiting at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Changhai Hospital · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing indomethacin in Pancreatitis — 6 open to participants now, 6 under way, 1 of them phase 3. Indomethacin · Pancreatitis.
Among the 20 studies testing indomethacin in Pancreatitis, this one is the 6th largest by planned enrollment, is one of 2 that started in 2025, is one of 7 in phase 4, and was the 18th registered.
558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.
Browse Pancreatitis studies →6 of the 20 studies testing indomethacin in Pancreatitis are open now, in 5 countries. Recruiting first, the newest first:
Air Force Military Medical University, China · Sites in China
Ages 18–90
Peking Union Medical College Hospital · Sites in China
Ages 18–80
Moti Lal Nehru Medical College · Sites in India
Ages 18–65
Chinese University of Hong Kong · Sites in China, Hong Kong, Thailand
Ages 18–99
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Indomethacin: first FDA approval 1965 (INDOCIN). What it is approved for, and how studies give it, is on its page →
Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 7 · Phase 4 7
First in 2005; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 1,366 is above the median of 100 across 349 interventional studies indexed under Pancreatitis.
Median enrollment 492 across the 20 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 20 has an industry lead sponsor. The 10 most frequent:
Changhai Hospital is the lead sponsor of 355 studies on the registry; 136 are open to participants now.
16 studies in Pancreatitis by Changhai Hospital: 7 open now, 7 under way, none of them phase 3. Of 6 finished, 1 (17%) have results posted.
Among the 16 studies in Pancreatitis by Changhai Hospital, this one is one of 2 that started in 2025, is one of 2 in phase 4, and was the 12th registered.
Changhai Hospital’s Pancreatitis studies by the year they started, since 1990.
1 of the studies testing indomethacin in Pancreatitis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07071441Air Force Military Medical University, ChinaIndomethacin vs Diclofenac for Preventing PEP | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing indomethacin in Pancreatitis, from their registry updates:
Among Changhai Hospital’s 16 in Pancreatitis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Endoscopic Retrograde Cholangiopancreatography (ERCP) is a widely used procedure for diagnosing and treating pancreatic and biliary diseases. Despite its benefits, ERCP carries a risk of post-procedure pancreatitis (PEP), which occurs in approximately 12.2% of cases and can significantly increase healthcare costs and patient morbidity. Preventing PEP is crucial for improving patient outcomes and reducing the economic burden of ERCP.
Nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, have been shown to be effective in reducing the incidence of PEP when administered rectally before ERCP. The standard dose recommended by guidelines is 100mg, which has been associated with a significant reduction in PEP rates. However, higher doses of NSAIDs can increase the risk of adverse events, including gastrointestinal bleeding and renal impairment. Therefore, there is a need to determine whether a lower dose can provide similar benefits without increasing these risks.
This multicenter, non-inferiority, double-blind, randomized controlled trial will be conducted in China. Participants will be adults aged 18 or older scheduled for ERCP. They will be randomly assigned in a 1:1 ratio to either the low-dose (50mg) or standard-dose (100mg) indomethacin group. The intervention will be administered rectally 30 minutes before the ERCP procedure. The study will follow a double-blind design, ensuring that both patients and investigators are unaware of the treatment allocation.
The results of this trial could significantly influence clinical practice by providing evidence on the effectiveness of a lower dose of indomethacin in preventing PEP. This could lead to a reduction in the risk of adverse events associated with higher doses and potentially decrease healthcare costs without compromising patient safety. By optimizing the dosing of indomethacin, this study aims to improve the safety and cost-effectiveness of ERCP procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients randomized to this intervention receive 50mg indomethacin
Drug: low dose indomethacin
patients randomized to this intervention receive 100mg indomethacin
Drug: standard dose indomethacin
Patients randomized to this intervention receive 100mg indomethacin suppositories within 30 min before ERCP.
Patients randomized to this intervention receive 50mg indomethacin suppositories within 30 min before ERCP.
The Proportion of Subjects in Each Study Group With Post-ERCP Pancreatitis
Time frame: Within 48 hours after ERCP
The Proportion of Subjects in Each Study Group With Moderate-severe Post-ERCP Pancreatitis
Time frame: Within one month of ERCP
Rate of Overall ERCP-related complications
ERCP-related complications include post-ERCP pancreatitis, gastrointestinal bleeding, perforation or infection according to Cotton Criteria.
Time frame: Within one month of ERCP
Rate of ERCP-related perforation
Time frame: Within one month of ERCP
Rate of ERCP-related infection
Time frame: Within one month of ERCP
Rate of ERCP-related bleeding
Time frame: Within one month of ERCP
Rate of NSAIDs-related complications
NSAIDs-related complications include: acute kidney injury, allergic reaction, gastrointestinal bleeding, myocardial infarction, cerebrovascular accident, and death
Time frame: Within one month of ERCP
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Nov 2026, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Indomethacin